Vitamin D and the skin

Clinics in Dermatology

Volumn 28, Issue 6, 2010, Pages 663-668

  Shahriari, Mona ^a   Kerr, Philip E ^a   Slade, Karren ^a   Grant Kels, Jane E ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; PARATHYROID HORMONE; PLACEBO; SUNSCREEN; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ADRENAL SUPPRESSION; ARTICLE; CALCIUM METABOLISM; CANCER INCIDENCE; CANCER RISK; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL TYPE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFECT; HUMAN; IMMUNOREGULATION; LICHEN SCLEROSUS ET ATROPHICUS; MORPHEA; NUTRITIONAL DEFICIENCY; NUTRITIONAL STATUS; PATIENT COMPLIANCE; PHOSPHATE METABOLISM; PHOTOSYNTHESIS; PRIORITY JOURNAL; PSORIASIS; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN ATROPHY; SKIN DISEASE; SUNLIGHT PROTECTION; SYSTEMIC DISEASE; VITAMIN BLOOD LEVEL; VITAMIN INTAKE; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

DIETARY SUPPLEMENTS; HUMANS; NEOPLASMS; PSORIASIS; SKIN DISEASES; SKIN PHYSIOLOGICAL PHENOMENA; SUNSCREENING AGENTS; ULTRAVIOLET RAYS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 77958550238     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2010.03.030     Document Type: Article

References (54)

1. MacLaughlin J.A., Anderson R.R., Holick M.F. Spectral character of sunlight modulates photosynthesis of previtamin D3 and its photoisomers in human skin. Science 1982, 216:1001-1003.
2. Kragballe K. Treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol 1992, 27:1001-1008.
3. Kragballe K. Calcipotriol: a new drug for topical psoriasis treatment. Pharm Toxicol 1995, 77:241-246.
4. Roenigk H., Howard M. Psoriasis 1998, 497-505. Informa Healthcare, New York. 3rd ed.
5. Holick M.F. Vitamin D Deficiency. N Engl J Med 2007, 357:266-281.
6. Garland C.F., Gorham E.D., Mohr S.B., Garland F.C. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009, 19:468-483.
7. Preston D.S., Stern R.S. Nonmelanoma cancers of the skin. N Engl J Med 1992, 327:1649-1662.
8. Kricker A., Armstrong B.K., English D.R. Sun exposure and non-melanocytic skin cancer. Cancer Causes Control 1994, 5:367-392.
9. Elwood J.M., Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997, 73:198-203.
10. Armstrong B.K., Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol 2001, 63:8-18.
11. Osterlind A., Tucker M.A., Stone B.J., Jensen O.M. The Danish case-control study of cutaneous malignant melanoma. II Importance of UV-light exposure. Int J Cancer 1988, 42:319-324.
12. Norman A.W. Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am J Clin Nutr 1998, 67:1108-1110.
13. Matsuoka L.Y., Wortsman J., Haddad J.G., Kolm P., Hollis B.W. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol 1991, 127:536-538.
14. Wolpowitz D., Gilchrest B. The Vitamin D question: how much do you need and how should you get it?. J Amer Acad Dermatol 2006, 54:301-317.
15. Gandini S., Raimondi S., Gnagnarella P., Doré J.F., Maisonneuve P., Testori A. Vitamin D and skin cancer: a meta-analysis. Eur J Cancer 2009, 45:634-641.
16. Bagot M., Charue D., Lescs M.C., Pamphile R., Revuz J. Immunosuppressive effects of 1,25-dihydroxyvitamin D3 and its analogue caciportriol on epidermal cells. Br J Dermatol 1994, 130:424-431.
17. Van Der Kerkhof P.C.M. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol 1995, 132:675-682.
18. Cunningham B.B., Landells I.D.R., Langman C., Sailer D.E., Paller A.S. Topical calcipotriene for mophea/linear scleroderma. J Am Acad Dermatol 1998, 39:211-215.
19. LeRoy E.C. Connective tissue synthesis by scleroderma skin fibroblasts in cell cultures. J Exp Med 1972, 135:1351-1362.
20. Boelsma E., Pavel S., Ponec M. Effects of calcitriol on fibroblasts derived from skin of scleroderma patients. Dermatology 1995, 191:226-233.
21. Bottomly W.W., Jutley J., Wood E.J., Goodfield M.D.J. The effect of calcipotriol on lesional fibroblasts from patients with active morphoea. Acta Derm Venereol (Stockh) 1995, 75:364-366.
22. Humbert P.G., Dupond J.L., Rochefort A., et al. Localized scleroderma-response to 1,25-dihydroxyvitamin D3. Clin Exp Dermatol 1990, 15:396-398.
23. Humbert P., Delaporte E., Dupond J.L., et al. Treatment of localized scleroderma with oral 1,25-dihydroxyvitamin D3. Eur J Dermatol 1994, 4:21-23.
24. Hulshof M.M., Pavel S., Breedveld F.C., Dijkmans B.A.C., Vermeer B.J. Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 1994, 130:1290-1293.
25. Ihn H., Sato S., Fujimoto M., Kikuchi K., Takehara K. Clinical significance of serum level of soluble interleukin-2 receptor in patients with localized scleroderma. Br J Dermatol 1996, 134:843-847.
26. Bhalla A.K., Amento E.P., Serog B., Glimcher L.H. 1,25-dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 1984, 133:1748-1754.
27. Kreuter A., Gambichler T., Sauermannn K., Jansen T., Altmeyer P., Hoffmann K. Extragenital lichen sclerosus successfully treated with topical calcipotriol: evaluation by in vivo confocal laser scanning microscopy. Br J Dermatol 2002, 146:332-333.
28. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
29. Scragg R., Sowers M., Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004, 27:2813-2818.
30. Cannell J.J., Vieth R., Umhau J.C., et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006, 134:1129-1140.
31. Van der Mei I.A., Ponsonby A.L., Dwyer T., et al. Past exposure to sun, skin phenotype and risk of multiple sclerosis: case-control study. Br Med J 2003, 327:316.
32. International Agency for Research on Cancer Vitamin D and cancer 2008, Vol 5. International Agency for Research on Cancer, Lyon.
33. Studzinski G.P., Moore D.C. Sunlight-can it prevent as well as cause cancer?. Cancer Res 1995, 55:4014-4022.
34. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007, 85:1586-1591.
35. Gorham E.D., Garland C.F., Garland F.C., et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Medicine 2007, 32:210-216.
36. Wactawski-Wende J., Kotchen J.M., Anderson G.L., et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006, 354:684-696.
37. Holick M.F. Calcium plus vitamin D and the risk of colorectal cancer. N Engl J Med 2006, 354:2287-2288.
38. Garland C.F., Gorham E.D., Mohr S.B., et al. Vitamin D and prevention of breast cancer: pooled analysis. J Biochem Mol Biol 2007, 103:708-711.
39. Moon S.J., Fryer A.A., Strange R.C. Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers. Mutat Res 2005, 571:207-219.
40. Goodwin P.J., Ennis M., Pritchard K.I., Koo J., Hood N. Vitamin D deficiency is common at breast cancer diagnosis and is associated with a significantly higher risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 BC. J Clin Oncol 2008, 26(suppl). Abstract 511.
41. Ng K., Meyerhardt J.A., Wu K., et al. Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol 2008, 26:2984-2991.
42. Chlebowski R.T., Johnson K.C., Kooperberg C., et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2007, 100:1581-1591.
43. Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, Version 1.0 2001, IARC Press, Lyon.
44. Norval M., Wulf H.C. Does chronic sunscreen use reduce vitamin D production to insufficient levels?. Br J Dermatol 2009, 161:732-736.
45. Matsuoka L.Y., Ide L., Wortsman J., et al. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab 1987, 64:1165-1168.
46. Matsuoka L.Y., Wortsman J., Hollis B. Use of topical sunscreen for the evaluation of regional synthesis of vit D3. J Amer Acad Dermatol 1990, 22:772-775.
47. Marks R., Foley P.A., Jolley D., et al. The effect of regular sunscreen use on vitamin D levels in an Australian population. Arch Dermatol 1995, 131:415-421.
48. Marks R. Use of sunscreens does not risk vitamin D deficiency. BMJ 1999, 319:1066.
49. Farrerons J., Barnadas M., Rodriguez J., et al. Clinically prescribed sunscreen (sun protection factor 15) does not decrease serum vitamin D concentration sufficiently either to induce changes in parathyroid function or in metabolic markers. Br J Dermatol 1998, 139:422-427.
50. Querings K., et al. 25-Hydroxyvitamin D-deficiency in renal transplant recipients: an underrecognized health problem. J Clin Endocrinol Metab 2006, 91:526-529.
51. Querings K., Reichrath J. A plea for detection and treatment of vitamin D deficiency in patients under photoprotection, including patients with xeroderma pigmentosum and basal cell nevus syndrome. Cancer Causes Control 2004, 15:219-220.
52. Reichrath J. Skin cancer prevention and UV-protection: how to avoid vitamin D-deficiency?. Br J Dermatol 2009, 161:54-60.
53. Holick M.F. Sunlight "D" ilemma: risk of skin cancer or bone disease and muscle weakness. Lancet 2001, 357:961.
54. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999, 69:842-856.